Trafficking regulation of proteins in Alzheimer’s disease by Shangtong Jiang et al.
REVIEW Open Access
Trafficking regulation of proteins in Alzheimer’s
disease
Shangtong Jiang1,2†, Yanfang Li2†, Xian Zhang2, Guojun Bu2,3, Huaxi Xu1,2,4 and Yun-wu Zhang2*
Abstract
The β-amyloid (Aβ) peptide has been postulated to be a key determinant in the pathogenesis of Alzheimer’s
disease (AD). Aβ is produced through sequential cleavage of the β-amyloid precursor protein (APP) by β- and
γ-secretases. APP and relevant secretases are transmembrane proteins and traffic through the secretory pathway in
a highly regulated fashion. Perturbation of their intracellular trafficking may affect dynamic interactions among these
proteins, thus altering Aβ generation and accelerating disease pathogenesis. Herein, we review recent progress
elucidating the regulation of intracellular trafficking of these essential protein components in AD.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder characterized clinically by cognitive and
memory dysfunction, accompanied by classical hallmark
pathologies such as intraneuronal neurofibrillary tangles
(NFTs) and extracellular amyloid plaques [1-3]. NFTs
are enriched with hyperphosphorylated microtubule-asso-
ciated protein tau (MAPT) [2], which can be phospho-
rylated by multiple protein kinases. Amyloid plaques
comprise a heterogeneous population of proteolytically-
generated small β-amyloid peptides (Aβ) [1,4,5]. Mounting
evidence indicates that overproduction/aggregation of Aβ
in the brain is a primary cause of AD. According to the
“amyloid cascade hypothesis”, neurotoxic Aβ may trigger
a cascade of complex neurodegenerative events leading to
synaptic dysfunction, NFT formation and eventually
neuron loss in affected brain areas [6-9].
Aβ is generated from amyloid beta (A4) precursor pro-
tein (APP). APP can be processed by amyloidogenic and
non-amyloidogenic pathways. Amyloidogenic processing
involves initial APP cleavage by β-secretase within the
ectodomain, leading to the release of a soluble APP frag-
ment called sAPPβ. The remaining membrane-anchored
APP β-carboxyl-terminal fragment (β-CTF) is then
cleaved by the γ-secretase complex within the lipid bilayer,
resulting in the production of Aβ peptide and the APP
intracellular domain (AICD). Alternatively, processing
within the non-amyloidogenic pathway involves APP
cleavage by α-secretase within the Aβ domain. The α-
cleavage releases the extracellular domain of APP called
sAPPα. The remaining membrane-bound fragment is
called APP α-CTF and can be further processed by γ-
secretase to generate AICD and a p3 peptide that is rap-
idly degraded [1,10]. Whether APP is processed through
the amyloidogenic pathway by β-secretase or through the
non-amyloidogenic pathway by α-secretase greatly de-
pends on colocalization between APP and these secre-
tases, which in turn is dependent on their subcellular co-
distribution. Hence, comprehensive elucidation of the
mechanisms responsible for regulating the intracellular
trafficking of APP and related secretases are important as-
pects in our understanding of AD and AD pathogenesis.
Regulated trafficking of APP
APP and its trafficking route within the cell
APP is a ubiquitously-expressed type I transmembrane
protein belonging to a family comprising three members:
APP, APP-like protein 1 and APP-like protein 2, all of
which share a highly conserved extracellular region con-
taining Kunitz protease inhibitor (KPI), E1 and E2 do-
mains [11,12]. However, only APP contains the Aβ region.
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There are three major APP protein isoforms: APP770,
APP751 and APP695. The longer isoforms APP770 and
APP751 contain the KPI domain, whereas APP695 is
devoid of this domain and is the predominant iso-
form expressed in the brain [13,14]. APP participates in
multiple cellular events including cell adhesion, neurite
outgrowth, neuronal migration, protein transport, cell sig-
naling and synaptogenesis. For a more complete review
on the function of APP please see [1].
Full-length APP is synthesized in the endoplasmic
reticulum (ER) and transported through the Golgi/trans-
Golgi network (TGN) apparatus where APP undergoes
posttranslational modifications such as glycosylation and
phosphorylation during maturation. TGN is also the
major site of resident APP in neurons [15-17]. Full-length
APP can be transported to the cell surface in TGN-
derived secretory vesicles. At the plasma membrane APP
is either cleaved by α-secretase to produce sAPPα [18] or
re-internalized within clathrin-coated vesicles to the endo-
some. APP in the endosome can either be recycled back
to cell surface or be delivered to the lysosome for degra-
dation (Figure 1) [19,20]. Aβ production involves multiple
intracellular organelles [15-17,21,22]. Typically, increased
APP delivery to or decreased APP internalization from the
cell surface favors the non-amyloidogenic processing,
whereas elevated retention of APP in acidic compartments
such as endosomes promotes amyloidogenic processing
and consequent Aβ production.
APP structure and post-translational modification affect its
trafficking
The intracellular domain of APP is key in regulating APP
trafficking through interactions with various cytosolic traf-
ficking factors. A highly conserved YENPTY motif (amino
acids 682–687 in APP695) within APP intracellular do-
main is the major binding site for a number of intracel-
lular adaptors such as APP-binding, family A (APBA,
previously called MINT) members and APP-binding,
family B, member 1 (APBB1, previously called Fe65) [23].
Mutation within this motif can attenuate the interna-
lization of APP, thereby decreasing Aβ generation [24].
Recently, the extracellular domain of APP has also been
shown to affect its trafficking: the KPI domain located in
the APP751 extracellular region promotes sorting of
APP751 to the plasma membrane, accompanied by de-
creased Aβ formation in comparison to the neuronal
enriched, KPI domain-absent APP695 isoform. Mutation
in the KPI domain of APP751 results in its retention in
the ER and elevated Aβ production [25].
APP can be phosphorylated at sites S655 and T668 (based
on APP695 numbering) and APP phosphorylation may also
affect its trafficking. A YTSI (amino acids 653–656 in
APP695) motif within the APP intracellular domain is
associated with APP internalization and Golgi polarized
sorting in MDCK epithelial cells; and phosphorylation of
S655 within this motif promotes APP retrieval from the
endosome to TGN [26,27]. Phosphorylation of APP T668
Figure 1 Typical trafficking route of APP, BACE1, α-secretase and γ-secretase. Newly synthesized APP, BACE1, α-secretase and γ-secretase
traffic through the secretory pathway, from the ER to Golgi/TGN and to the plasma membrane, during which process retrieval may occur and APP
may be cleaved to generate Aβ. At the plasma membrane APP is largely subjected to non-amyloidogenic processing by α-secretase to release sAPPα.
Un-cleaved APP and various secretases at the plasma membrane may undergo endocytosis via early endosome to late endosome/lysosome for
degradation. Acidic endosome/lysosome provides optimal environment for BACE1 activity and APP is mainly subjected to amyloidogenic processing
for Aβ production in these compartments. In addition, a fraction of these proteins in endosome can be either recycled back to plasma membrane or
retrieved back to TGN.
Jiang et al. Molecular Neurodegeneration 2014, 9:6 Page 2 of 13
http://www.molecularneurodegeneration.com/content/9/1/6
facilitates amyloidogenic APP processing and Aβ ge-
neration [28]. Although direct evidence linking T668
phosphorylation and APP trafficking is scarce, T668 phos-
phorylation may interfere APP’s interaction with other pro-
teins and thus potentially affect its processing/trafficking
[29]. Indeed, phosphorylated APP is found to be preferen-
tially enriched at nerve terminals and plasma membrane
in neurons, and accumulates in pathological damaged
regions of AD brains [30].
APP can be ubiquitinated for its proteasomal degra-
dation. But ubiquitination of APP may also inhibit
its endocytosis to endosomal compartment and thereby
lower Aβ generation. In support of this notion, the E3 ubi-
quitin ligase component FBL2 can promote APP ubiquiti-
nation and suppress its endocytosis [31]. In addition, an
ubiquitin-like protein, ubiquilin-1 (UBQLN1), can stimu-
late K63-linked polyubiquitination at APP K688 to inhibit
APP maturation and delay APP proteolytic processing
through APP sequestration primarily within the Golgi
apparatus [32,33]. Interestingly, variants in the UBQLN1
gene have been proposed to be associated with AD
[34], implying that UBQLN1-mediated APP trafficking/
processing might be altered in AD.
The LDLR family in APP trafficking
The low density lipoprotein receptor (LDLR) family con-
sists of a number of cell surface receptors of diverse
functions, including the LDLR, LDLR-related protein 1
(LRP1), LDLR-related protein 1B (LRP1B), LDLR-related
protein 2 (LRP2), LDLR-related protein 4 (LRP4), LDLR-
related protein 5 (LRP5), LDLR-related protein 6 (LRP6),
LDLR-related protein 8 (LRP8, also known as APOER2),
LDLR-related protein 10 (LRP10), LDLR class A domain
containing 3 (LDLRAD3), sortilin-related receptor, (LDLR
class) A repeats containing (SORL1, also known as SorLA
or LR11), etc. [35,36]. Many LDLR family members act as
receptors for apolipoprotein E (APOE), whose allelic poly-
morphisms are strongly associated with late-onset AD
[37], further implicating the involvement of LDLR family
members in AD. Recently several LDLR family members
have been shown to modulate APP trafficking/processing.
For example, LRP1 can bind APP directly or indirectly
through the adaptor protein APBB1/Fe65 and promote
rapid APP endocytosis to early endosomes to promote Aβ
production [38,39]. In contrast LRP1B can compete with
LRP1 for APP interactions and due to its comparatively
slow rate of endocytosis compared to LRP1, LRP1B retains
APP at cell surface and suppresses Aβ generation [40,41].
Another LDLR family member, LRP8/APOER2 can
interact with APP intracellularly via APBA/MINT and
DAB1 [42,43] or extracellularly via SPON1 (also known
as f-spondin) [44]. APP trafficking and resultant non-
amyloidogenic or amyloidogenic processing is dependent
on the nature of LRP8/APOER2 and APP interactions
(intracellularly or extracellularly) and specific linker
proteins involved. A new member of LDLR family,
LRP10, is found to shuttle between plasma membrane,
TGN and endosome [45,46], and interacts with the APP
ectodomain to sequester APP in Golgi compartments,
thereby reducing APP β-processing and consequent Aβ
generation [47].
The best characterized LDLR family member in AD is
SORL1, a multifunctional neuronal receptor that binds
APOE and APP. Genetic studies have identified multiple
inherited variants in the SORL1 gene associated with
late-onset AD [48-51]. In addition, SORL1 level is de-
creased dramatically in frontal cortex and lymphoblasts
from AD patients [52]. A correlation between decreased
SORL1 expression and impaired cognitive function is
also observed [53]. Although the exact physiological
function of SORL1 has yet to be determined, its ho-
mology with sorting receptors that are involved in the
transportation between plasma membrane, endosomes
and Golgi suggests the protein trafficking function
of SORL1 [54,55]. Indeed, SORL1 has been found to
localize mainly in late endosomal and Golgi com-
partments and overexpression of SORL1 redistributes
APP to the Golgi and reduces Aβ generation, whereas
downregulation of SORL1 promotes APP sorting into
Aβ-generating compartments to aggravate Aβ produc-
tion [51,56-58]. These data indicate that SORL1 plays
important roles in AD pathology by regulating the
localization and processing of APP.
The RAB GTPase family in APP trafficking
RABs comprise a subfamily of small molecular weight
GTPases within the RAS superfamily which regulates
cellular trafficking. In humans, over 60 RAB family
members have been described so far [59]. RABs func-
tion as molecular switches, alternating between active
GTP-bound and inactive GDP-bound forms [60]. RABs
regulate protein transport mainly by tethering/docking
vesicles to target compartments [60]. Multiple RABs
have been implicated in regulating APP trafficking. For
example, RAB1B plays a key role in APP transport from
the ER to Golgi. A dominant-negative RAB1B mutant
blocks APP ER/Golgi transport and significantly inhi-
bits Aβ secretion [61]. In addition, RAB6 functions
as a negative regulator of APP anterograde transport
through TGN or as a positive modulator of APP retro-
grade transport from post-Golgi vesicles back to TGN
or Golgi cisternae; and a dominant-negative RAB6
mutant facilitates the anterograde transport of APP in
the secretory pathway to promote α-cleavage [62].
Furthermore, RAB8 facilitates APP transport between
the Golgi apparatus and plasma membrane and mu-
tations in RAB8 results in the reduction of sAPPα
secretion [63,64].
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The SNX family in APP trafficking
Sorting nexins (SNXs) are a diverse group of cellular traf-
ficking proteins that characteristically comprise a cano-
nical phospholipid-binding domain. The ability of SNXs
to bind specific phospholipids, as well as their propensity
to form protein-protein complexes, suggests a role for
these proteins in membrane trafficking and protein sor-
ting [65,66]. Recently, several SNX members have been
found to participate in APP metabolism/Aβ generation:
SNX33 interacts with the endocytic GTPase dynamin
and overexpression of SNX33 reduces the rate of APP
endocytosis in a dynamin-dependent manner, leading to
enhaced α-cleavage at the cell surface [67]. In addition,
SNX17 can bind to APP in the early endosome and
SNX17 downregulation causes a decline in steady-state
levels of APP with a concomitant increase in Aβ pro-
duction [68].
The APBA/MINT family in APP trafficking
The APBA/MINT family is an adaptor protein family
comprising APBA1/MINT1, APBA2/MINT2 and APBA3/
MINT3. All three proteins are enriched in neurons and
contain a phosphotyrosine binding (PTB) domain in the
central region and two tandem carboxyl-terminal PDZ
(PSD-95, Drosophila disks-large, ZO-1) domains. Moun-
ting evidence indicates that the APBA/MINT family is
involved in multiple cellular activities relevant to neuro-
nal protein transport and consequent synaptic function
[69-71]. APBA/MINT proteins can interact with the APP
YENPTY motif through their PTB domains to fine-tune
APP trafficking and processing [70,71]. For instance,
APBA1/MINT1 has been found to modulate both
secretory and endocytic trafficking of APP and its meta-
bolism [71]. In addition, APBA2/MINT2 can be phosphor-
ylated by SRC to accelerate APP endocytosis and enhance
APP sorting to autophagosomes, leading to enhanced
intracellular Aβ accumulation. Conversely, an APBA2/
MINT2 phospho-resistant mutant promotes APP traffic-
king in the recycling pathway to the cell surface, thus en-
hancing Aβ secretion [72]. Furthermore, APBA1/MINT1
or APBA2/MINT2 may function as a linker to mediate
co-endocytosis of LRP8/APOER2 and APP, thereby eleva-
ting Aβ production [42,73]. Finally, APBA3/MINT3 also
plays an obligatory role in mediating APP trafficking from
the TGN to the plasma membrane and its deficiency
reroutes APP trafficking to the endosomal/lysosomal
pathway [74].
Other proteins involved in APP trafficking
In addition to general trafficking modulators, several other
proteins have also been proposed to regulate APP traf-
ficking. For example, we and others have shown that pre-
senilin 1 (PS1), the catalytic component of the γ-secretase
complex, can regulate APP intracellular trafficking: PS1
deficiency results in increased APP trafficking to the
plasma membrane, whereas familiar AD-linked PS1 mu-
tants dramatically reduce cell surface delivery of APP [75].
PS1 has been proposed to interact with APP and this
might be a potential mechanism for its function in regu-
lating APP trafficking. Alternatively, PS1 might regulate
APP trafficking through interactions with trafficking fac-
tors such as RAB family members and phospholipase D1
(PLD1) [76-80]. PLD1 is a phospholipid-modifying en-
zyme regulating membrane trafficking events and PLD1
overexpression itself also promotes APP transport from
TGN to the plasma membrane [79,80].
Regulated trafficking of the β-secretase BACE1
BACE1 and its trafficking pathways within the cell
It is well accepted that beta-site APP-cleaving enzyme 1
(BACE1) is the dominant β-secetase enzyme for APP
[81-84]. BACE1 is a 501 amino acid long type-I trans-
membrane aspartyl protease comprising a prodomain with
significant homology to other aspartyl protease pre-
cursors. Overexpression or downregulation of BACE1 in-
duces or inhibits APP processing and Aβ generation both
in vitro and in vivo [81-85]. Several studies find that
BACE1 level and activity are elevated significantly in AD
brain [86,87]. In addition, in an APP overexpression AD
mouse model, deletion of BACE1 can abolish Aβ pa-
thology and rescue cholinergic dysfunction and memory
deficits [88-90]. These findings suggest that BACE1 may
be a good therapeutic target for AD treatment. On the
other hand, more recent studies have found that in
addition to APP, there are other BACE1 substrates includ-
ing neuregulin 1 [91,92], p-selectin glycoprotein ligand-1
[93], ST6GAL1 [94], β-subunits of voltage-gated sodium
channels [95], etc. This raises a possibility that inhibition
of BACE1 might affect proper processing of these proteins
and cause unwanted side effects. BACE1 null mice do de-
velop several phenotypic abnormalities such as reduced
body size, hyperactive behavior, decreased grip strength
and elevated pain sensitivity [91,92,96]. Recently Eli Lilly’s
BACE1 inhibitor LY2886721 was also found to cause liver
toxicity during its Phase 2 clinical trial. However, it is un-
clear whether abnormal phenotypes found in BACE1 null
mice are generated during developmental stages or during
aging; and LY2886721-caused liver toxicity is not believed
to be attributed to BACE1 inhibition. Furthermore,
BACE1 heterozygous knockout mice have no reported ab-
normal phenotypes so far and heterozygous knockout of
BACE1 still can reduce Aβ deposition in AD mice [97,98].
Hence, moderate inhibition of BACE1 activity may still be
a good strategy for AD treatment.
Like other aspartic proteases, immature BACE1 con-
taining the short prodomain is initially synthesized in
the ER and subsequently transported to the Golgi appa-
ratus where the prodomain is removed by FURIN or
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other FURIN-like proteases [99-102]. Removal of this pro-
domain leads to a ~2-fold increase of BACE1 activity
[103]. BACE1 can also be N-glycosylated and mature
BACE1 is exported either to the plasma membrane or to
the endosomal compartment. Plasma membrane localized
BACE1 can be internalized into the endosome, whereby
BACE1 can be recycled to the plasma membrane or
transferred to late endosomal/lysosomal compartments
(Figure 1). As optimal BACE1 activity is achieved in acidi-
fied environments, BACE1 is mainly found in acidic sub-
cellular compartments such as endosome [82,104-107].
Therefore, any modulator that can affect BACE1 shuttling
between TGN, the plasma membrane and endosome may
play a role in APP processing and Aβ generation.
The GGA family in BACE1 trafficking
Golgi-localized γ-adaptin ear-containing ADP ribosylation
factor binding proteins (GGAs) are a family of monomeric
clathrin adaptor proteins that participate in transport of
cargo proteins from TGN to endosome [108]. Mammalian
GGAs (GGA1, GGA2, and GGA3) all comprise an amino-
terminal VHS (VPS-27, Hrs, and STAM), an intermediary
GAT (GGA and Tom1) and a carboxyl-terminal GAE
(γ-adaptin ear) domain [108]. VHS and GAT domains are
highly conserved among GGA1, GGA2 and GGA3 [109].
Recruitment of GGAs from the cytosol to TGN is me-
diated by the GAT domain [109-111]. Subsequent GGA
VHS domain binding to the acidic cluster-dileucine
(ACDL) sorting motif within the cytoplasmic tails of
selective cargo proteins then sorts the selected cargo
into clathrin-coated vesicles that are delivered to the
endosome [112].
The BACE1 DISLL (amino acids 496–500) sequence is
an ACDL motif located in the BACE1 cytoplasmic domain
and can be recognized by the GGAVHS domain [113,114].
Previous studies indicate that GGA1 modulates BACE1 re-
trieval from the endosome to TGN in a phosphorylation-
dependent manner. Serine phosphorylation within the
BACE1 DISLL motif enhances BACE1-GGA interaction
[115]. Phosphorylated BACE1 is efficiently transported
from endosomes to TGN, whereas non-phosphorylated
BACE1 enters a direct recycling route to the plasma mem-
brane [114,116,117]. Overexpression of GGA1 decreases
Aβ secretion, while suppression of GGA1 conversely ele-
vates Aβ secretion [116]. In addition, a recent study shows
that GGA1 but not GGA2 or GGA3 can modulate SORL1
endocytic traffic and consequent APP traffic to the endocy-
tic recycling compartment [118]. Furthermore, mutation of
BACE1 S498 to a non-phosphorylatable residue enhances
BACE1 targeting to SORL1-positive compartments [118].
In contrast, GGA3 is proposed to mediate targeting of
BACE1 to lysosomes for degradation [119-121]. In AD
brains, GGA3 level is significantly decreased and inversely
correlated with elevated levels of BACE1. Downregulation
of GGA3 also increases BACE1 levels [120,121]. More-
over, BACE1 can be ubiquitinated at K501 and a GGA3
mutant with reduced ubiquitin-binding ability fails to
regulate BACE1 levels, implying that GGA3 may also
regulate BACE1 via interactions with ubiquitin sorting
machinery [122].
The retromer complex and the SNX family in BACE1
trafficking
The mammalian retromer complex is composed of VPS35,
VPS29, VPS26, SNX1 and SNX2 [123]. Retromer is re-
quired for protein endosomal sorting and is closely linked
to the endosome-to-Golgi retrieval pathway. Retromer was
first identified to sort VPS10 from endosome back to the
TGN in yeast [123]. Recent studies have identified some
retromer interacting proteins including SORL1 [124] and
BACE1 [125]. Suppression of VPS35 expression decreases
BACE1 trans-Golgi localization and retains BACE1 in the
endosome, the optimal environment for BACE1 activity.
Consistently, heterozygous deletion of VPS35 in AD mice
results in a significant increase in Aβ level in the mouse
hippocampus, accompanied with AD-like phenotypes in-
cluding cognitive memory deficits, defective long-term po-
tentiation (LTP) and impaired postsynaptic glutamatergic
neurotransmission in early adult age [125]. One recent
study also found that downregulation of VPS35 in neu-
rons results in increased colocalization of APP with the
BACE1 in early endosomes and consequently elevated Aβ
levels [126]. Similarly, downregulation of another retromer
component VPS26 induces the accumulation of BACE1 in
endosome [114]. Coincidently, the levels of VPS35 and
VPS26 are found to be downregulated in AD [127].
The existence of two SNX family members, SNX1 and
SNX2 within the retromer complex has provided a link for
SNXs in regulating BACE1 trafficking. SNX6, a SNX2-like
retromer regulator, can interact with BACE1 and negatively
regulate its retrograde transport from early endosomes to
TGN, retaining BACE1 in endosome [128]. We recently
identified SNX12 as another BACE1-interacting protein
and demonstrated its role in modulating BACE1 trafficking
between the cell surface and early endosome [129].
Other proteins involved in BACE1 trafficking
There is evidence suggesting that endocytosis of APP and
BACE1 are spatially separate: in contrast to clathrin-
dependent APP endocytosis, BACE1 internalization to
early endosome is found to be regulated by the small
GTPase ADP ribosylation factor 6 (ARF6). Modulation of
ARF6 levels or its activity affects endosomal sorting
of BACE1 and altered APP processing/Aβ production.
Furthermore, APP is cleaved by BACE1 in RAB5-positive
early endosome and sorting of BACE1 from ARF6-positive
towards RAB5-positive early endosome depends on the
BACE1 DISLL motif [130].
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In addition to its carboxyl-terminus, the transmembrane
domain of BACE1 may also affect its trafficking. We
recently found that the heavy components of the CUTA
protein can interact with the BACE1 transmembrane
region. Downregulation of CUTA decelerates BACE1
transport from Golgi/TGN to the plasma membrane and
reduces steady-state levels of cell surface BACE1, thus
resulting in increased Aβ generation [131]. Furthermore,
BACE1 can interact with the reticulon family proteins and
this is mediated by BACE1 transmembrane domain [132].
The reticulon family has four members, RTN1, RTN2,
RTN3 and RTN4 (also known as Nogo), and is involved in
various physiological processes such as membrane traf-
ficking, axonal growth and apoptosis [133]. Overex-
pression of any reticulon protein has been shown to
substantially reduce Aβ production. In neurons, BACE1
mainly colocalizes with RTN3, whose overexpression
can block BACE1 in the ER and thus inhibit BACE1 ac-
tivity for Aβ generation [134,135]. Interestingly, recep-
tors of reticulon have also been found to mediate Aβ
production but this is through their interaction with
APP. Increased interaction between reticulon receptor
and APP can reduce surface expression of APP and
favors APP β-cleavage [136,137].
Regulated trafficking of the γ-secretase complex
The γ-secretase complex
BACE1-digested APP CTFs are subsequently cleaved
by the γ-secretase complex to release Aβ. In addition,
γ-secretase cleaves a series of functionally important
substrates such as NOTCH [138] and tyrosinase [139].
γ-secretase activity is produced from a high molecular
weight complex consisting of at least four transmem-
brane components: presenilin (PS, with two mammalian
homologs as PS1 and PS2), nicastrin, anterior pharynx-
defective-1 (APH-1), and presenilin enhancer-2 (PEN2)
[140,141]. PS1/2 have an undetermined number of
transmembrane domains [142] and undergo endo-
proteolytic cleavage to generate PS amino-terminal frag-
ments (NTFs) and CTFs. PS NTF and CTF form a
functional heterodimer, each contributing a highly con-
served aspartate residue indispensable for γ-secretase
activity [143]. Nicastrin is a type I transmembrane
glycoprotein considered to be the scaffolding protein
within the γ-secretase complex. Nicastrin may also act
as the γ-secretase receptor [144]. The seven-transmem-
brane APH-1 interacts with nicastrin to form a stable
intermediate in an early assembly stage of the γ-
secretase complex [140,141], whereas the two-pass
transmembrane component PEN2 regulates PS endo-
proteolysis [145,146]. Each of these four components is
necessary for γ-secretase activity and deficiency in any
of these factors dramatically impairs the enzymatic
activity.
Assembly of the γ-secretase complex and its trafficking
route within the cell
Although aspects of γ-secretase complex formation and
distribution have yet to be fully elucidated, a predicted
model for the assembly, maturation, and trafficking of the
γ-secretase complex has been proposed. In this model, the
four components of the γ-secretase complex are synthe-
sized in the ER, where they await incorporation into stable
complex. Complex formation initially begins with the
association of APH-1 and nicastrin to form an early inter-
mediate subcomplex. Full-length PS is then incorporated
into and stabilized within the complex. Subsequent assem-
bly of PEN2 drives the conversion of the full-length PS
into active NTF/CTF heterodimers in ER and Golgi com-
partments [140,147]. During its transit through Golgi/
TGN, nicastrin undergoes complete glycosylation, thus
transforming the γ-secretase complex into its mature
form. The γ-secretase complex in large part shuttles
between the ER and Golgi, whereas stabilized mature
γ-secretase complex is transported to the plasma mem-
brane. γ-secretase at the membrane can then undergo
endocytosis to endosomes, and subsequent trafficking to
late endosomes/multivesicular bodies or the lysosome
(Figure 1) [148-151].
Factors regulating γ-secretase trafficking and activity
In addition to its function as the catalytic core of the
γ-secretase complex, PS1 has been shown to modulate
trafficking of several transmembrane proteins including
APP [75]. Since PS1 interacts with a series of trafficking
modulator proteins such as RAB family members and
PLD1, PS1 might exert its trafficking regulation through
these interactions [152]. Conversely, these trafficking
modulators may also reciprocally regulate PS1 traffic-
king. For example, we find that PLD1 interacts with PS1
and overexpression of PLD1 promotes cell surface accu-
mulation of PS1 in an APP-independent manner [153].
A trafficking regulation role has been proposed for APP
[154] and we also find that APP can reciprocally regulate
the intracellular trafficking of PS1 and other γ-secretase
components. APP deficiency results in elevated transpor-
tation of PS1/γ-secretase from TGN to the cell surface,
thereby enhancing NOTCH cleavage [153]. Additionally,
APP can function as a kinesin-I membrane receptor and
mediates axonal transport of PS1 and BACE1 [155].
The recently identified postsynaptic protein ARC also
interacts with PS1 and participates in sorting PS1 to
early and recycling endosomes to enhance amyloido-
genic APP processing. Aβ production can be blocked by
interrupting ARC association with PS1/γ-secretase and
genetic deletion of ARC decreases Aβ load in a trans-
genic AD mouse model [156].
The G protein-coupled receptor (GPCR) β2-adrenergic
receptor is associated with PS1 where agonist-induced
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β2-adrenergic receptor endocytosis mediates trafficking of
PS1/γ-secretase to late endosomes and lysosomes to
enhance Aβ production [157]. Another GPCR, GPR3 is
also found to be a modulator of Aβ production: over-
expression of GPR3 increases the formation and cell sur-
face localization of the mature γ-secretase components,
accompanied with stimulated Aβ generation but not
NOTCH processing. In contrast, GPR3 deficiency pre-
vents Aβ accumulation both in vitro and in vivo. More-
over, GPR3 is highly expressed in normal human brain
regions implicated in AD and its level is elevated in spor-
adic AD brain [158]. Interestingly, recently it was sug-
gested that both β2-adrenergic receptor and GPR3 exert
their effects on Aβ generation through interacting with β-
arrestin 2, a member of the arrestin family [159]. Arrestins
are GPCR-interacting scaffold proteins and can inhibit G
protein coupling to GPCRs, leading to GPCR desen-
sitization and even mediating a G protein-independent
signaling pathway [160]. β-arrestin 2 is found to interact
with APH-1, redistribute the γ-secretase complex toward
detergent-resistent membranes and increase its catalytic
activity [159]. The degree of Aβ production stimulation is
also correlated with GPCR-β-arrestin 2 binding and recep-
tor trafficking to endocytic vesicles [161]. Moreover, a
subset of GPCRs including GPR3 and PTGER2, are found
to be associated with APP when internalized via β-arrestin
2, thereby increasing APP amyloidogenic processing as
well [161]. Coincidently, another arrestin family member,
β-arrestin 1, can interact with APH-1 and facilitate the
formation of nicastrin/APH-1 subcomplex and mature
γ-secretase complex. β-arrestin 1 expression is upregu-
lated in the brains of sporadic AD patients and transgenic
AD mice, whereas deletion of β-arrestin 1 in AD mice re-
sults in reduced Aβ generation, diminished Aβ pathology
and improved cognition [162].
The retention in ER sorting receptor 1 (RER1), a mem-
brane factor mediating protein retrieval from Golgi to the
ER, has been found to regulate γ-secretase trafficking. In
one study, RER1 was found to bind to the transmembrane
region of nicastrin and retrieve unincorporated nicastrin
from the cis-Golgi back to the ER. Since RER1 competes
with APH-1 for nicastrin binding, depletion of RER1 re-
sulted in elevated γ-secretase complex assembly/activity
and increased Aβ secretion [163]. In another study, RER1
was found to bind to the first transmembrane domain of
PEN2 and retrieve unassembled PEN2 to the ER [164].
Both studies suggest that RER1 may be critical in monito-
ring quality control during γ-secretase complex assembly.
Recently, RER1 overexpression was also shown to de-
crease both γ-secretase localization on the cell surface and
Aβ secretion, whereas RER1 downregulation had opposite
effects [165]. Furthermore, increased RER1 levels could
decrease mature APP and increase immature APP, resul-
ting in less surface accumulation of APP [165].
ATP-binding cassette transporter-2 (ABCA2) is a
component responsible for retrograde trafficking of lipo-
protein-derived cholesterol from late endosome/lysosome
to the ER, and has been genetically linked to AD [166,167].
It has been recently shown that ABCA2 depletion can
reduce γ-secretase complex formation due to alterations in
protein levels, post-translational modification, and sub-
cellular localization of nicastrin, thus affecting the γ-
processing of APP and Aβ generation [168].
Regulated trafficking of the α-secretase ADAM10
α-secretase, ADAM10 and its trafficking route within the cell
α-secretase-mediated APP cleavage leads to the release of
sAPPα, and competitively antagonizes APP amyloidogenic
processing and Aβ generation. The α-secretase processing
pathway is Protein Kinase C-dependent and its activity
can be modulated by various molecules such as the puri-
nergic P2Y2 receptor, pituitary adenylate cyclase activating
polypeptide, muscarinic receptors and NMDA receptors
[169-172]. In addition to APP, several other proteins in-
cluding prion, NOTCH receptors, ephrins, tumor necrosis
factor α and cadherins have also been identified as
α-secretase substrates [119,173-175].
So far, several ADAM (A Disintegrin and Metallopro-
tease) family members including ADAM9, ADAM10
and ADAM17 have been implicated as potential APP
α-secretases. These type-I transmembrane ADAM compo-
nents are prominently expressed in adult central nervous
system. However, the expression of ADMA10 is relatively
high compare to those of ADAM9 and ADAM17 in neu-
rons [176-178] and conditional knockout of ADAM10 in
mouse neurons nearly abolishes neuronal sAPPα gene-
ration [179]. Together, this suggests that ADAM10 is the
major functional α-secretase in neurons [180,181]. In AD
patients, the protein level of ADAM10, α-secretase activity
and consequent sAPPα levels are found to be decreased
significantly in platelets and temporal cortex regions
[182,183]. In contrast, ADAM9 and ADAM17 thus
far have only been shown to participate in regulated
α-secretase cleavage [181,184].
Newly-synthesized ADAM10 in the ER has a proprotein
convertase recognition sequence between the prodomain
and the catalytic regions. During its secretory trafficking
to TGN and cell surface (Figure 1), ADAM10 can be
cleaved by PC7 or FURIN to yield a mature, active form
[185-187]. In neurons, α-secretase functions predo-
minantly at the cell surface [188], with minor α-secretase
activity observed in TGN [189-191].
Regulated trafficking of ADAM10
An arginine-rich (723RRR) sequence within the ADAM10
intracellular C-terminal tail is required for its retention
in the ER and attenuates trafficking to the cell surface.
Mutation of the second arginine within the 723RRR
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sequence is sufficient to allow ADAM10 exit from the
ER and enhance ADAM10 distribution to the neuronal
cell surface [192].
Protein interactions can influence ADAM10 localization.
For instance, interactions with synapse-associated protein-
97 (SAP97), a protein involved in dynamic transport of
proteins to the excitatory synapses, facilitates ADAM10
targeting to the postsynaptic membrane. ADAM10-SAP97
interaction is triggered by NMDA receptor activation,
thus promoting the non-amyloidogenic processing of
APP. Conversely, disrupting ADAM10-SAP97 interaction
redistributes ADAM10 localization from postsynaptic
membranes, thereby suppresses non-amyloidogenic APP
processing. As a consequence, this results in Aβ accumu-
lation, MAPT hyperphosphorylation, and impaired be-
havioral performance and synaptic dysfunction in mice,
thereby recapitulating early-stage AD phenotypes [193].
In the hippocampus of AD patients, the association of
ADAM10 with SAP97 is found to be reduced [194], im-
plying a dysfunction in SAP97-mediated ADAM10 sorting
in AD. Interestingly, while long-term depression can pro-
mote SAP97-dependent ADAM10 distribution and acti-
vity in synaptic membranes, LTP can induce ADAM10
endocytosis and reduce ADAM10 activity through the
association of the clathrin-adaptor AP2. Furthermore,
ADAM10-AP2 association is found to be enhanced in AD
patients [195]. These findings indicate that SAP97 and
AP2 are critical components in controlling ADAM10
localization and activity at synapses to modulate patho-
physiology in AD.
Conclusions
Although APP is a well-characterized substrate of α-, β-
and γ-secretases, the physiological relevance of the various
APP processing pathways is far from clear. Amyloidogenic
Aβ generation from APP clearly contributes to AD-
associated neurotoxicity and plays a central role in the
pathogenesis of AD. A wealth of experimental evidence
demonstrates APP cleavage by different secretases at dis-
tinct cellular sites, implying the importance of the subcel-
lular co-distribution of APP and various secretases in Aβ
generation. Indeed, APP processing is a complicated and
dynamic process during which a number of adaptors/
linkers, motor molecules and membrane proteins work to-
gether to facilitate proper sorting of APP and its secre-
tases. This review covers some of the salient aspects of
intracellular trafficking regulation of APP and secretases.
Future investigation is expected to enhance our under-
standing of how dysregulation of protein trafficking can
contribute to AD pathogenesis and may potentially reveal
new strategies in AD treatment.
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